PADRINI, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.049
AS - Asia 7.998
EU - Europa 3.569
SA - Sud America 1.327
AF - Africa 1.284
OC - Oceania 123
Continente sconosciuto - Info sul continente non disponibili 121
Totale 28.471
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.355
SG - Singapore 2.428
VN - Vietnam 1.369
CN - Cina 1.342
HK - Hong Kong 860
BR - Brasile 821
IT - Italia 494
FI - Finlandia 380
FR - Francia 368
DE - Germania 361
GB - Regno Unito 279
BD - Bangladesh 245
IN - India 243
UA - Ucraina 209
SE - Svezia 181
PL - Polonia 168
RU - Federazione Russa 130
IQ - Iraq 118
TR - Turchia 113
AR - Argentina 94
NL - Olanda 89
SA - Arabia Saudita 88
CA - Canada 87
JP - Giappone 85
PH - Filippine 85
PK - Pakistan 81
ID - Indonesia 76
ZA - Sudafrica 72
CO - Colombia 66
EC - Ecuador 65
UZ - Uzbekistan 59
MX - Messico 57
VE - Venezuela 55
MY - Malesia 54
JO - Giordania 50
PY - Paraguay 50
PS - Palestinian Territory 49
MA - Marocco 48
MU - Mauritius 47
AO - Angola 44
ES - Italia 44
ET - Etiopia 44
AL - Albania 43
GA - Gabon 43
IL - Israele 42
PE - Perù 42
SN - Senegal 42
BO - Bolivia 41
KE - Kenya 41
RS - Serbia 41
UG - Uganda 41
BE - Belgio 40
CR - Costa Rica 40
JM - Giamaica 40
KG - Kirghizistan 40
KR - Corea 40
AE - Emirati Arabi Uniti 39
ME - Montenegro 39
CV - Capo Verde 38
CZ - Repubblica Ceca 38
DK - Danimarca 38
IE - Irlanda 38
ML - Mali 38
PA - Panama 38
AT - Austria 37
CI - Costa d'Avorio 37
KZ - Kazakistan 37
UY - Uruguay 37
BB - Barbados 36
CH - Svizzera 36
HN - Honduras 36
NP - Nepal 36
BJ - Benin 35
LY - Libia 35
MG - Madagascar 35
TN - Tunisia 35
AU - Australia 33
BZ - Belize 33
CL - Cile 33
DO - Repubblica Dominicana 33
EG - Egitto 33
GH - Ghana 33
HR - Croazia 33
IR - Iran 33
LU - Lussemburgo 33
MR - Mauritania 33
CW - ???statistics.table.value.countryCode.CW??? 32
DZ - Algeria 32
AZ - Azerbaigian 31
LC - Santa Lucia 31
MD - Moldavia 31
TT - Trinidad e Tobago 31
AM - Armenia 30
BG - Bulgaria 30
GT - Guatemala 30
LV - Lettonia 30
MK - Macedonia 30
PR - Porto Rico 30
SI - Slovenia 30
TJ - Tagikistan 30
Totale 27.025
Salva come PNG Salva come JPEG
Città #
Singapore 1.492
Fairfield 1.360
San Jose 1.353
Ashburn 1.212
Woodbridge 892
Hong Kong 782
Chandler 770
Jacksonville 749
Houston 716
Ann Arbor 646
Wilmington 553
Seattle 496
Cambridge 489
Ho Chi Minh City 370
Santa Clara 354
Princeton 303
Hanoi 290
Boardman 263
Los Angeles 254
Beijing 229
Helsinki 182
Dong Ket 163
Lauterbourg 154
San Diego 139
Nanjing 117
Bytom 113
Des Moines 105
Medford 104
New York 104
Roxbury 97
Padova 83
Munich 77
São Paulo 67
Da Nang 65
Guangzhou 61
Chicago 58
Baghdad 57
Orem 56
Tokyo 52
Tashkent 50
Haiphong 48
Amman 45
Buffalo 42
Dakar 42
Libreville 42
Kampala 40
Milan 40
Rome 40
Bamako 38
Addis Ababa 37
Council Bluffs 37
Panama City 37
Shenyang 36
Bridgetown 35
Luanda 35
Nairobi 35
Praia 35
Abidjan 34
Bishkek 33
London 33
Podgorica 33
Cotonou 32
Montevideo 32
Nanchang 32
Warsaw 32
Castries 31
Johannesburg 31
Antananarivo 30
Changsha 30
Dallas 30
Nouakchott 30
Frankfurt am Main 29
Jeddah 29
Baku 28
Hải Dương 28
Lima 28
Norwalk 28
Atlanta 27
Riyadh 27
Tianjin 27
Tirana 27
Willemstad 27
Accra 26
Conakry 26
Dublin 26
Kingston 26
Kuala Lumpur 26
Montreal 26
Phoenix 26
Quito 26
San José 26
Yerevan 26
Brooklyn 25
Dushanbe 25
Havana 25
Lahore 25
Managua 25
Mumbai 25
Asunción 24
Can Tho 24
Totale 17.347
Salva come PNG Salva come JPEG
Nome #
Phthalates and heavy metals as endocrine disruptors in food: A study on pre-packed coffee products 494
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naive Patients with Non-Valvular Atrial Fibrillation 333
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 307
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. 298
Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients with Alzheimer Disease 287
Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable? 280
Perioperative Analgesic Efficacy and Plasma Concentrations of S(+)-Ketamine in Continuous Epidural Infusion During Thoracic Surgery. 274
A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy 268
Ranolazine-Induced Severe Bladder Hypotonia 263
Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors 262
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial 258
Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms 256
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. 248
R-warfarin anticoagulant effect 245
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer’s disease 240
Towards model-based diagnosis of von Willebrand disease 238
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. 235
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. 235
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer 234
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. 234
Calcium-antagonist effects of norbormide on isolated perfused heart and cardiac myocytes of guinea-pig: a comparison with verapamil 231
A model-based support for diagnosing von Willebrand disease 231
Macrolides for KCNJ5–mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism 231
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes 228
Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction 228
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study 227
A model-based protocol for the diagnosis of von Willebrand disease 227
Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world 227
Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients 226
Adaptation of the QT interval to heart rate changes in isolated perfused guinea-pig heart: influence of amiodarone and d-sotalol. 225
VKORC1, CYP2C9 AND CYP4F2 GENETIC BASED ALGORITHM FOR WARFARIN DOSING. PRELIMINARY RESULTS OF A PROSPECTIVE ITALIAN STUDY 224
A model-based approach to the automatic diagnosis of von Willebrand disease 224
VERAPAMIL AND NORVERAPAMIL PLASMA-LEVELS IN INFANTS AND CHILDREN DURING CHRONIC ORAL TREATMENT 223
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment 221
A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease 220
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function 218
Pharmacokinetics of Pentoxifylline and Its Main Metabolites in Patients With Different Degrees of Heart Failure Following a Single Dose of a Modified-Release Formulation 216
Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis 215
Antihypertensive therapy in patients on chronic lithium treatment for bipolar disorders 209
Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties 203
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. Ther Drug Monit. 2005 Dec;27(6):816-8. 201
Effect of CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function 199
Liver dysfunction markedly decreases the inhibition of cytochrome P450IA2-mediated theophylline metabolism by fluvoxamine 198
Antiarrhythmic drug plasma concentrations in ambulatory patients 197
Identifying type Vicenza von Willebrand disease 196
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor 196
UNDULY ENHANCED RESPONSE TO TOLVAPTAN IN A WOMAN SHOWING SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION: AN INVESTIGATION OF POSSIBLE CAUSES 195
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age 192
Pharmacokinetics of lidocaine after bilateral ESP block 190
Ibuprofen enantiomers in premature neonates with patent ductus arteriosus: Preliminary data on an unexpected pharmacokinetic profile of S(+)-ibuprofen 189
AJMALINE TEST IN A PATIENT WITH CHRONIC-RENAL-FAILURE - A PHARMACOKINETIC AND PHARMACODYNAMIC STUDY 188
Neurohumoral effects of digitalis 188
Renal clearance of N-1-Methylnicotinamide is a marker of liver dysfunction in cirrhosis 185
Classification of thymidylate synthase gene enhancer region polymorphisms 179
Effects of phospholipase C on the electrical and mechanical activity of guinea pig taenia coli. 178
Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. 175
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms 174
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy 172
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. 172
Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium 171
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours 169
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. 169
Effect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function 168
DETERMINATION OF LORAJMINE AND ITS METABOLITE AJMALINE IN PLASMA AND URINE BY A NEW HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD 167
[The relevance of the receptor system in the determination of hypertension]. 167
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure 167
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old 166
Liver dysfunction markedly decreases the inhibition of CYP1A2-mediated theophylline metabolism by fluvoxamine 166
Digitalici 164
EFFECTS OF PINACIDIL ON GUINEA-PIG ISOLATED PERFUSED HEART WITH PARTICULAR REFERENCE TO THE PROARRHYTHMIC EFFECT 158
Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man 156
A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele 155
Relationships between bioelectrical impedance parameters and fluorouracil pharmacokinetics 155
Pharmacodynamic variability of flecainide assessed by QRS changes 155
Correlations between the enantio- and regio-selective metabolisms of warfarin 155
VKORC1, CYP2C9 and CYP4F2 pharmacogenetics: relevance in warfarin maintenance dose prediction among italian patients. 154
Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers 154
Renal excretion and diuretic effect of furosemide in patients with ascitic liver cirrhosis 154
Digitalis glycosides and plasma renin activity 153
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis 151
Intralesional topotecan in advanced ovarian cancer: A clinical report, based on a preclinical study 149
Tolerance to the repolarization effects of sotalol during long term treatment 149
The calcium-channel blocker, Verapamil, does not improve portal pressure in patients with alco¬holic cirrhosis. 148
EFFECTS OF PINACIDIL IN ISOLATED PERFUSED GUINEA-PIG HEART 148
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays 145
Convective and adsorptive removal of β2-microglobulin during predilutional and postdilutional hemofiltration 145
Effects of cardiopulmonary bypass on vancomycin plasma concentration decay. 143
Once per week oral administration of amiodarone in the prophylaxis of supraventricular paroxysmal tachycardia 143
Vasorelaxant effect of norbormide, a selective vasoconstrictor of rat microvasculature. 141
Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. 141
FARMACOLOGIA CLINICA DELL'IPERTENSIONE ARTERIOSA 139
Apolipoprotein E (APOE) and warfarin dosing in an Italian population. 139
A report on the positive inotropic action of amrinone 138
Farmacologia Clinica Cardiovascolare (V Ed.) 137
[Anti-arrhythmia drugs of the '80s: something new with respect for the old]. 137
Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis 136
Long-term persistence of antianginal effect of oral verapamil in chronic stable angina 136
Electrophysiological interactions between pinacidil, a potassium channel opener, and class 1 antiarrhythmic agents in guinea-pig isolated perfused heart. 134
Vasorelexant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature 134
Present and future trends in research and clinical applications of inodilators. 133
Totale 19.696
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.806
article - articoli 68.508
book - libri 363
conference - conferenze 0
curatela - curatele 0
other - altro 271
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.374
Totale 152.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.898 0 301 184 157 79 120 71 208 91 39 213 435
2022/20231.677 381 155 26 181 287 237 10 109 211 9 63 8
2023/2024651 31 121 93 60 38 37 32 17 18 15 102 87
2024/20253.452 9 280 172 160 528 74 116 252 258 150 660 793
2025/202613.325 412 1.155 1.826 1.887 1.212 557 1.958 1.275 1.456 797 457 333
2026/2027552 423 129 0 0 0 0 0 0 0 0 0 0
Totale 28.471